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Abstract
Background—HIV infection and antiretroviral therapy are associated with dyslipidemia, but the
association between regional adipose tissue depots and lipid levels is not defined.
Methods—The association of MRI-measured visceral (VAT) and regional subcutaneous adipose
tissue (SAT) volume with fasting lipid parameters was analyzed by multivariable linear regression
in 737 HIV-infected and 145 control men from the study of Fat Redistribution and Metabolic
Change in HIV Infection (FRAM).
Results—HIV-infected men had higher median triglycerides (TG) (170mg/dl vs. 107mg/dl,
p<0.0001), lower high density lipoprotein (HDL-C) (38mg/dl vs. 46mg/dl, p<0.0001) and lower
low density lipoprotein (LDL-C) (105mg/dl vs. 125mg/dl, p<0.0001) than controls. After
adjustment, greater VAT was associated with higher TG and lower HDL-C in both HIV-infected
and control men, while greater leg SAT was associated with lower TG in HIV-infected men with a
similar trend in controls. More upper trunk SAT was associated with higher LDL-C and lower
HDL-C in controls, while more lower trunk SAT was associated with higher TG in controls. After
adjustment, HIV infection remained strongly associated (p<0.0001) with higher TG (+76%, CI:
53, 103), lower LDL-C (−19%, CI: −25,−12), and lower HDL-C (−18%, CI: −22,−12).
Conclusions—HIV-infected men are more likely than controls to have higher TG and lower
HDL-C, which promote atherosclerosis, but also lower LDL-C. Less leg SAT and more VAT are
important factors associated with high TG and low HDL-C in HIV-infected men. The reduced leg
SAT in HIV-infected men with lipoatrophy places them at increased risk for pro-atherogenic
dyslipidemia.
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Abnormalities of lipid and lipoprotein levels are prevalent among HIV-infected individuals.
HIV infection itself is associated with reductions in HDL cholesterol (HDL-C) and LDL
cholesterol (LDL-C), with increases in triglycerides appearing with development of
AIDS[1-4]. Therapy with HIV protease inhibitors (PI) is associated with increases in
triglycerides, LDL-C and total cholesterol[5-9]. A syndrome of HIV-associated
lipodystrophy was described that included peripheral fat wasting and central fat gain,
associated with increased triglycerides and cholesterol and decreased HDL-C; this syndrome
was initially attributed to treatment with PIs [10]. Subsequent studies demonstrated that PI-
induced changes in lipid and lipoprotein levels are seen before any changes in body
composition[9,11-13]. Studies linking HIV lipodystrophy to dyslipidemia have mostly used
clinical definitions and varied in their inclusion of peripheral fat wasting and central fat
gain[10,14-17]. It is now recognized that subcutaneous lipoatrophy is the HIV-specific
change and that peripheral lipoatrophy and central lipohypertrophy are not linked in the
same syndrome[18-21].
The clinical assessment of lipoatrophy underestimates the changes in HIV compared to
direct measurement of adipose tissue volume. Even HIV-infected subjects who do not have
the clinical syndrome of lipoatrophy may have significantly less subcutaneous adipose tissue
(SAT) in their lower body (legs and lower trunk) than healthy controls [20,21]. The amount
of visceral adipose tissue (VAT) is independent of leg SAT in HIV-infected men [20,21].
Given the association of total adipose tissue with dyslipidemia in the general population, a
major aim of the study of Fat Redistribution and Metabolic Change in HIV Infection
(FRAM) was to define the relationship between regional adipose tissue volume
measurements by MRI with fasting triglycerides, directly measured LDL-C and HDL-C in
HIV-infected men with comparison to control men while taking into account demographic
factors and lifestyle factors such as physical activity. A second goal was to assess the
contribution of HIV and HIV-related factors to these metabolic parameters after adjusting
for factors known to affect lipids, especially adipose tissue.
Methods
Subjects
The methods of the Study of Fat Redistribution and Metabolic Changes in HIV infection
(FRAM), which was conducted between June 2000 and September 2002, have previously
been described in detail [20,22]. HIV-infected participants enrolled in FRAM were selected
from coded lists of patients seen in 16 HIV or infectious disease clinics or cohorts in the US
and were representative of HIV-infected men living in the U.S.[22,23]. Control subjects
were recruited for FRAM from two centers of the Coronary Artery Risk Development in
Young Adults (CARDIA) study[24,25] that followed participants longitudinally enrolled in
the Visceral Fat and Metabolic Rate in Young Adults (VIM) ancillary study of CARDIA.
CARDIA participants were originally recruited as a population-based sample of healthy 18-
to 30-year old Caucasian and African-American men and women from four cities in 1985-86
for a longitudinal study of cardiovascular risk factors. The VIM ancillary study recruited
participants from two of the four CARDIA Centers in 1995-96. VIM enrolled approximately
100 CARDIA participants from each of the race-gender groups with BMI distributed
similarly above and below race-gender specific medians of the population-based CARDIA
study. Participants in the CARDIA study were stratified for the 2 races and sexes.
Institutional Review Boards at all participating sites approved the study protocol and
consent process.
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Of the 980 men in FRAM, 737 HIV-infected and 145 control men were included in this
analysis. Among the HIV-infected men, 72 were excluded due to missing lipid or MRI data
and 16 were excluded due to a recent opportunistic infection. Among the control men, 10
were excluded due to missing lipid or MRI data. For comparisons of HIV and control
characteristics, 390 (of the 737) HIV-infected men of similar age to control men were
included. The results in women will be reported separately.
Study Procedures
Standardized questionnaire instruments were used to assess physical activity, alcohol intake,
smoking, illicit drug use, and adequacy of food intake of FRAM participants[25-27]. Food
intake was based on self-report from a validated instrument, where subjects were asked
whether they had adequate access or resources to get the food needed. Medical history was
also assessed. Research associates interviewed HIV-infected participants and reviewed
medical charts to determine the dates of use of individual antiretroviral medications.
Blood was drawn following a 12-hour overnight fast and sent to Covance central laboratory
(Indianapolis, IN) for determination of total cholesterol (TC), HDL-C, triglycerides and
directly measured LDL-C. LDL-C was measured using the LDL-C Plus assay (Roche
Diagnostics, Indianapolis, IN). The lower limit of detection of the triglyceride assay is 12
mg/dL (the inter- and intra-assay coefficients of variation were 2.88%-3.25% and 1.09%,
respectively). The lower limit of detection of the HDL assay is 10 mg/dL (the inter- and
intra-assay coefficients of variation were 5.45%-7.41% and 1.4%, respectively). The lower
limit of detection of the LDL-C Plus assay is 3.1 mg/dL (the inter- and intra-assay
coefficients of variation were 2.61%-2.68% and 1.7%, respectively). CD4+ T lymphocyte
counts were determined by flow cytometry (Becton Dickinson, Franklin Lakes, NJ), and
HIV RNA levels determined by the Amplicor HIV-1 MONITOR test (Roche Diagnostics,
Branchburg, NJ) with a linear range from 400 - 750,000 copies/mL.
Weight and height were determined using standard methods. Whole body magnetic
resonance imaging was performed to quantify body composition using a standard
protocol[28] as described previously[20] [22]. MRI scans were segmented using image
analysis software (Tomovision Inc., Montreal, Canada). Volume of each tissue for the space
between two consecutive slices was calculated via a mathematical algorithm[29]. Using
these methods we quantified adipose tissue volume in the following sites: leg, lower trunk
(abdomen and back, ending at last slice where liver area is greater than lung area), upper
trunk (chest and back), arm, total subcutaneous adipose tissue (SAT), visceral adipose tissue
(VAT) and total adipose tissue.
Statistical Methods
For numerical values, data are presented as median values and 95% Confidence Interval
(CI), with distribution free confidence intervals constructed for the median[30] and p-values
calculated using the Mann-Whitney U test. Fisher’s exact test was used for categorical
values. We did not adjust for multiple comparisons, because there were many inter-related
positive results that reinforced each other by fitting together in a coherent pattern.
To assess the independent associations of body fat depots and other factors with lipids, we
performed multivariable regression analysis in separate models for control and HIV-infected
subjects. Separate analyses were performed for each of the following lipids: triglycerides,
direct LDL-C, and HDL-C. In this first analysis, factors related to HIV infection were
initially excluded. The primary predictors were trichotomized amounts of adipose tissue
volume from anatomic sites measured by MRI: upper trunk, lower trunk, arm, leg and total
SAT, VAT and total fat. Trichotomized versions of the anatomic site measurements were
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created using tertile cut offs from the control group of men to facilitate comparison of
similar quantities of adipose tissue between control and HIV-infected men.
Demographic predictors unrelated to HIV infection, such as age and ethnicity, were also
included. The effect of age was modeled linearly, but with potentially different slopes in the
ranges 18 to 40, 40 to 50, and 50+ years old. Other predictors included as candidates in the
modeling were level of physical activity (quartiles based on control men), current smoking
status, current illicit drug use (marijuana, crack, cocaine, combination use of crack and
cocaine), adequate food consumption, and alcohol drinks used in the past year.
Separate multivariable linear regression models for HIV-infected and control men were built
using stepwise regression, with p=0.05 for entry and retention, testing for interactions of
ethnicity with other factors at each step; age and ethnicity were forced to be included in
every model. A fat depot was included in the model if testing showed statistical significance
at the 0.05 level. We tested for collinearity among fat depots and found it was not
substantial. We performed stepwise regression by evaluating possible models one by one,
rather than with an automated stepwise procedure, in order to avoid exclusion of
observations that had missing data only on unselected candidate variables. Because of their
skewed distribution, the lipids were log-transformed in all linear regression analyses; results
were back-transformed to produce estimated percentage effects of each factors. Adjusted
geometric mean lipid levels were obtained from the same models using the LSMEANS
statement in SAS Proc Mixed for each tertiled level of fat.
Another objective was to compare lipid levels among HIV-infected and control men after
adjusting for the common predictors measured in both groups. We used a stepwise
multivariable analysis similar to the first one, but with HIV vs. control added as a factor. We
tested for interactions of HIV and ethnicity with other factors at each step. For this analysis,
age was restricted to 33-45 years old and only data from Caucasians and African-Americans
were used to match the demographics of the controls.
In a further stepwise multivariable analysis, we tested whether the addition of factors related
to HIV infection affected the association of adipose tissue volumes with the lipids, using the
complete HIV-infected cohort. HIV related factors screened in the model were CD4 count,
HIV RNA levels, history of AIDS by OI and current antiretroviral therapy in models similar
to those previously presented, with current CD4 and HIV RNA forced to be included in the
model.
Results
The demographic and clinical characteristics of HIV-infected men of similar age to control
men are shown in Table 1, as are the characteristics of all HIV-infected men included in
analyses related to HIV factors. Compared to control men in the same age range, HIV-
infected men were more likely to smoke and more likely to report inadequate food intake,
but less likely to consume alcohol and to exercise. Body mass index (BMI) was lower in
HIV-infected than in control men, and HIV-infected men had less visceral adipose tissue
and less subcutaneous fat in each regional depot, as well as less total adipose tissue overall.
HIV-infected men in the age range of controls were similar to all HIV-infected men with
regard to HIV-related characteristics and antiretroviral use (Table 2).
Lipid and Lipoprotein Levels
Compared to controls, HIV-infected men had higher median triglyceride levels (170 mg/dl
vs. 107 mg/dl, p<0.001) but lower levels of HDL-C (38 mg/dl vs. 46 mg/dl, p<0.001), LDL-
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C (105 vs. 125, p<0.001), and total cholesterol (191 vs. 206, p = 0.003) (Figure 1). Results
were similar when stratified by race (data not shown).
The proportion of HIV-infected men with TG >150 mg/dl was higher compared to controls
(57% vs. 28%, p<0.001), as was the proportion with TG > 500 mg/dl (9% vs. 2%, p=0.004).
The proportion of HIV-infected men with HDL-C < 40 mg/dl was higher compared to
controls (54% vs. 27%, p<0.001). In contrast, the proportion of HIV-infected men with
LDL-C >130 mg/dl was lower than in controls (26% vs. 45%, p<0.001). HIV-infected men
were more likely to be on lipid lowering therapy than were control men (Table 3).
In both HIV-infected and control men, African-American race was associated with similarly
lower fasting triglyceride (HIV −22%, Control −23%) and higher HDL cholesterol (HIV
+12.5%, Control +12%) levels than Caucasians. There were no statistically significant racial
differences in LDL-C seen in either group (data not shown).
Regional Adipose Tissue Volume and Triglycerides, LDL-C and HDL-C
To assess the association of regional adipose tissue depots with lipids, we performed
multivariable analysis that included age, ethnicity, and lifestyle factors. Visceral adipose
tissue (VAT) was positively associated with triglycerides in both HIV-infected and control
men (Figure 2A). Lower trunk SAT was also positively associated with triglycerides in
control men, while there may be a weak positive association of lower trunk SAT with
triglycerides in HIV-infected men. In contrast, lower amounts of leg SAT were associated
with higher triglycerides in HIV-infected men, with a similar trend in control men.
Associations of adipose tissue with LDL-C appeared to be weaker (Figure 2B). The
association of arm SAT with LDL-C appeared to be opposite between HIV-infected and
control men (p=0.008). Arm SAT was positively associated with LDL-C in HIV-infected
men, although there was not a typical dose-response for adipose tissue volume, while arm
SAT appeared to be negatively associated with LDL-C in control men. In control men,
upper trunk SAT was positively associated with LDL-C, but there was little apparent
association of upper trunk SAT with LDL-C in HIV-infected men.
VAT was negatively associated with HDL-C in both HIV-infected and control men (Figure
2C). Upper trunk SAT was also negatively associated with HDL-C in control men. Leg SAT
showed little apparent association with HDL-C in HIV-infected or control men after
multivariable adjustment.
HIV Infection and Lipids
After adjustment for demographic and HIV-unrelated factors including adipose tissue
volume, HIV infection in men remained strongly associated with higher triglycerides, lower
LDL-C, and lower HDL-C compared to controls (Table 4). The percent effects after
adjustment (Table 4) were similar to the unadjusted effect (Figure 1).
Among HIV-infected men, little change was seen in the associations with adipose tissue
depots even after HIV-related factors (e.g., ARV) were included in the multivariable model
(data not shown). Among HIV-related factors, higher current CD4+ cell count was
associated with higher triglycerides and lower LDL-C, but showed no apparent association
with HDL-C (Table 5). A higher HIV viral load was associated with lower LDL-C and
HDL-C. Having a diagnosis of AIDS was associated with higher triglycerides even after
adjusting for current CD4+ cell count and HIV RNA.
Being on ritonavir was strongly and independently associated with higher triglycerides,
while being on abacavir showed a weaker, but statistically significant positive association
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with triglycerides. Treatment with nevirapine or efavirenz was associated with higher HDL-
C, while indinavir was associated with lower HDL-C. Associations of antiretroviral drugs
with LDL-C were weaker, and none reached statistical significance.
Discussion
HIV infection [1-4] and its therapies [5-9,12,31] are known to be associated with
dyslipidemia. We now report that HIV infection remains associated with higher
triglycerides, lower HDL-C and lower LDL-C than controls in this large study of HIV-
infected and control men even after adjustment for adipose tissue volumes directly measured
by MRI, as well as after adjustment for demographics and lifestyle factors. In HIV positive
men, inclusion of HIV-related factors such as CD4+ count, viral load and antiretroviral
drugs had little effect on the association of adipose tissue with lipids.
Most associations of adipose tissue volume with lipids were similar for HIV-infected and
control men. For example, more VAT was associated with higher triglycerides and lower
HDL-C in both HIV-infected and control men. Less leg SAT was associated with higher
triglycerides in HIV-infected men, and also likely in control men.
The leg depot is of particular interest due to the prevalence of HIV-associated lipoatrophy.
While clinical HIV-lipodystrophy has been associated with hypertriglyceridemia, past
studies have usually pooled lipoatrophy and lipohypertrophy [10,14-17]. Here we show that
lower amounts of leg SAT (the fat depot most affected with lipoatrophy in HIV-infected
men [20] are independently and negatively associated with hypertriglyceridemia. Studies of
familial and acquired lipodystrophy syndromes in HIV-uninfected patients have also shown
a link between lipoatrophy and hypertriglyceridemia [32-34]. To facilitate comparison of
similar quantities of adipose tissue in HIV-infected and control men, we used tertiles based
on cutoffs for control men. A similar quantitative relationship was found for HIV-infected
and control men; being in the highest tertile for leg SAT was associated with 29% lower
triglyceride levels. Given the prevalence of lipoatrophy in HIV-infected men, more HIV-
infected men fall into the ranges of low leg fat, contributing to hypertriglyceridemia.
VAT is positively associated with triglyceride levels in both HIV-infected and Control men.
We have shown previously that VAT and leg SAT are not inversely linked in HIV infection
[20,21], but that there are men with lipoatrophy who have high amounts of VAT [20]. Thus
HIV-infected men with both low leg SAT and increased VAT have two independent risk
factors for high triglycerides.
HIV-related factors also contribute to hypertriglyceridemia. The association between a
diagnosis of AIDS and higher triglycerides has previously been observed in men in the pre-
HAART era [2] and was found again here.
While more VAT is associated with lower HDL-C levels, the associations of leg SAT with
HDL-C were very small and did not approach statistical significance. After controlling for
HIV-related factors in the multivariable model, including ARV, little change was seen in the
association with adipose tissue depots. Higher HIV viral load was also associated with lower
HDL-C levels, consistent with the lower levels of HDL-C seen before the introduction of
effective combination antiretroviral therapy[2,35].
LDL-C levels do not strongly correlate with obesity or visceral adiposity in the general
population. Therefore, it is not surprising that we found only a weak relationship of VAT
with LDL-C. The associations with upper trunk and arm SAT found here are novel, but
these depots are not traditionally measured. We have also found that upper trunk SAT is
independently associated with insulin resistance in both HIV-infected and control
Wohl et al. Page 6













subjects[36]. The significance of these associations needs further exploration. The
associations of CD4+ counts and HIV viral load are consistent with the previously described
effect of HIV on lowering LDL [2,3].
It is important to note that the median triglyceride and LDL-C levels in our cohort of men
between 33 and 45 years of age remained in the normal ranges. More HIV-infected than
control men were on lipid lowering agents. Sensitivity analyses excluding those on lipid-
lowering therapy or controlling for those on lipid-lowering therapy showed little change in
the relationships of adipose tissue depots and HIV infection status to lipids. However, 12%
of HIV-infected men and 22% of Control men still had LDL-C levels above standard cutoffs
where behavioral or lipid-lowering therapy should be considered (LDL-C ≥160). Despite
this, only 27% of HIV-infected men and 3% of control men with LDL-C ≥160 were on lipid
lowering therapy. The higher prevalence of smoking in HIV-participants offers another area
in which cardiovascular risk reduction could be done.
A strength of our study is its size and direct measurements of regional adipose tissue
volume, which allowed for multivariable analysis of associations of depots and HIV related
factors with lipid levels. A limitation of our study is the cross-sectional design. Hence the
study risks confounding of ARV effects by other factors, such as prior outcomes
(participants may have been removed form a drug because of a metabolic effect, thus
decreasing or even reversing the association). Nevertheless, similar to other studies, we
found that being on ritonavir was associated with higher triglycerides[5,6,12,31] and being
on nevirapine or efavirenz was associated with higher HDL-C[37-39]. While use of older
antiretroviral drug regimens has declined greatly in industrialized nations, lipoatrophy
persists after discontinuation of the responsible ARV drugs. Furthermore, similar drug
regimens associated with lipoatrophy are still frequently used in the developing world. The
associations of adipose tissue with lipids and lipoproteins in this analysis were independent
of and not influenced by current ARV, hence can be extrapolated to current patients with
HIV-associated lipoatrophy or visceral obesity. Finally, the cross-sectional design also limits
the ability to make causal inferences regarding changes in HIV disease status. However, the
ability to adjust for regional adipose tissue depot volumes provides important information on
the link between those depots and HIV effects. The associations of regional fat distributions
with lipid levels in HIV infection, while similar to findings in the general population, will
require further validation in other cohorts.
In summary, HIV-infected men have higher triglycerides, lower HDL-C, and lower LDL-C
than control men that are independent of amounts of adipose tissue. Less leg SAT and more
VAT are important risk factors for adverse lipid profiles in men. Because leg fat is the fat
depot most affected in HIV associated lipoatrophy, HIV-infected men may be at particular
risk for hypertriglyceridemia as low leg fat adds to the effects of more VAT, ritonavir and
HIV infection itself. Increased VAT also is associated with lower HDL. These data define
the effects of body fat, HIV infection, and antiretroviral therapy that should help health care
providers and patients understand the metabolic complications of HIV infection and its
therapies.
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Lipid and lipoprotein levels stratified by HIV-status.
Levels are in mg/dL. Closed boxes: HIV+. Open boxes: Control. The data are from the HIV-
infected and Control men in the age range of 33-45. Median is indicated by black center
line, and the IQR (first and third quartiles) are the edges of the box. Whiskers denote Q1 – 1.
5× IQR and Q3 + 1.5 × IQR. Asterisks denote outliers beyond 1.5 × the IQR.
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Multivariable association of regional adipose tissue with lipid and lipoprotein levels in HIV-
infected and Control men (not age restricted).
A. Triglycerides. B. LDL Cholesterol. C. HDL Cholesterol.
Levels are in mg/dL.
Open: 1st Tertile (lowest amount of fat)
Light grey: 2nd Tertile
Dark grey: 3rd tertile (highest amount of fat)
Asterisks denote comparison with first tertile: *** p<.001, ** p <.01, * p < .05 Analyses
also control for demographic and lifestyle factors and include all HIV-infected men.
Italicized depots did not reach statistical significance and were not included in the model,
but are shown to facilitate comparison. Abbreviations: VAT = visceral adipose tissue; SAT
= subcutaneous adipose tissue.
Wohl et al. Page 12









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Wohl et al. Page 17
Table 3
Proportion of HIV-infected and control men on lipid lowering therapy
HIV+ Control P-value
Any lipid lowering therapy 13.8% 1.4% <.0001
 Statin 8.9% 0.7% 0.0003
 Fibrate 6.8% 0.0% 0.0004
 Other Hypolipidemic 0.0% 0.7% 0.27
Note: analysis is age-restricted and OI-excluded.
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Table 4
Multivariable association of HIV infection with lipid and lipoprotein levels.*
HIV vs. Control
% Effect 95% CI p-value
Triglycerides 76 (53,103) <.0001
LDL-C −19 (−25,−12) <.0001
HDL-C −18 (−22,−12) <.0001
*
multivariable, linear regression of combined HIV and Control populations controlling for demographics, lifestyle factors, and regional adipose
tissue volume.
Note: analysis is age-restricted and OI-excluded.
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